Oncolytics Biotech is a biotechnology business based in the US. Oncolytics Biotech shares (ONCY) are listed on the NASDAQ and all prices are listed in US Dollars. Oncolytics Biotech employs 29 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $2.23 |
|---|---|
| 52-week range | $1.09 - $3.39 |
| 50-day moving average | $2.55 |
| 200-day moving average | $1.83 |
| Wall St. target price | $7.34 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.34 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.23 from 2023-09-27
| 1 week (2023-09-21) | 1.83% |
|---|---|
| 1 month (2023-08-28) | 4.21% |
| 3 months (2023-06-28) | -7.85% |
| 6 months (2023-03-28) | 84.30% |
| 1 year (2022-09-28) | 72.87% |
|---|---|
| 2 years (2021-09-27) | 2.76% |
| 3 years (2020-09-28) | 31.95% |
| 5 years (2018-09-28) | 3.86 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -49.27% |
| Return on equity TTM | -101.26% |
| Profit margin | 0% |
| Book value | $0.34 |
| Market Capitalization | $173 million |
TTM: trailing 12 months
We're not expecting Oncolytics Biotech to pay a dividend over the next 12 months.
Oncolytics Biotech's shares were split on a 10:95 basis on 24 May 2018. So if you had owned 95 shares the day before before the split, the next day you'd have owned 10 shares. This wouldn't directly have changed the overall worth of your Oncolytics Biotech shares – just the quantity. However, indirectly, the new 850% higher share price could have impacted the market appetite for Oncolytics Biotech shares which in turn could have impacted Oncolytics Biotech's share price.
Over the last 12 months, Oncolytics Biotech's shares have ranged in value from as little as $1.09 up to $3.3942. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oncolytics Biotech's is 1.7488. This would suggest that Oncolytics Biotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Oncolytics Biotech Inc. , a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Everything we know about the Discord IPO, plus information on how to buy in.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.
Steps to owning and managing HGGG, with 24-hour and historical pricing before you buy.